{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:28:39Z","timestamp":1779942519064,"version":"3.53.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":141,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Foundation Medicine Inc."},{"name":"Joan and Irwin Jacobs Philanthropic Fund"},{"name":"Jon Schneider Memorial Cancer Research Fund"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30CA023100"],"award-info":[{"award-number":["P30CA023100"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K08CA168999"],"award-info":[{"award-number":["K08CA168999"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R21CA192072"],"award-info":[{"award-number":["R21CA192072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA226803"],"award-info":[{"award-number":["R01CA226803"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001071","name":"David Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001071","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kristen Ann Carr Fund"},{"name":"Foundation Medicine Inc."},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Blueprint Medicines"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incyte"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sequenom"},{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Omniseq"},{"name":"Foundation Medicine Inc."},{"name":"Guardant Health"},{"name":"Konica Minolta"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ejca.2020.04.002","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T21:15:15Z","timestamp":1589577315000},"page":"25-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Precision oncology: the intention-to-treat analysis fallacy"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4403-0271","authenticated-orcid":false,"given":"Jason K.","family":"Sicklick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-8621","authenticated-orcid":false,"given":"Ryosuke","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.04.002_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.trecan.2017.12.004","article-title":"Challenging standard-of-care paradigms in the precision oncology era","volume":"4","author":"Subbiah","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejca.2020.04.002_bib2","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/15384101.2015.1041695","article-title":"Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes","volume":"14","author":"Kurzrock","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejca.2020.04.002_bib3","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/0008-5472.CAN-17-1569","article-title":"Next-generation sequencing in the clinical setting clarifies patient characteristics and potential actionability","volume":"77","author":"Bieg-Bourne","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2020.04.002_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic characterization of metastatic breast cancers","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejca.2020.04.002_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41591-019-0442-2","article-title":"Molecular profiling in precision medicine oncology","volume":"25","author":"Le Tourneau","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2020.04.002_bib6","series-title":"Statistical issues in drug research and development","first-page":"331","article-title":"Intention to treat in clinical trials","author":"Fisher","year":"1990"},{"key":"10.1016\/j.ejca.2020.04.002_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.2.4582.769","article-title":"Streptomycin treatment of pulmonary tuberculosis","volume":"2","year":"1948","journal-title":"Br Med J"},{"key":"10.1016\/j.ejca.2020.04.002_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2229-3485.83221","article-title":"Intention-to-treat concept: a review","volume":"2","author":"Gupta","year":"2011","journal-title":"Perspect Clin Res"},{"issue":"5","key":"10.1016\/j.ejca.2020.04.002_bib9","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2020.04.002_bib10","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.002_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.04.002_bib12","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.002_bib13","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2020.04.002_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.002_bib15","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492030191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492030191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:18Z","timestamp":1760732778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492030191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":15,"alternative-id":["S095980492030191X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision oncology: the intention-to-treat analysis fallacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}